Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma

References

1. 1.↵
   2. Hartmann M,
   3. Heiland S,
   4. Harting I, et al

   . Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003;338:119–22 doi:10.1016/S0304-3940(02)01367-8 pmid:12566167

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Lee IH,
   3. Kim ST,
   4. Kim HJ, et al

   . Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol 2010;76:48–51 doi:10.1016/j.ejrad.2009.05.013 pmid:19500931

   CrossRefPubMed
3. 3.↵
   2. Xu W,
   3. Wang Q,
   4. Shao A, et al

   . The performance of MR perfusion-weighted imaging for the differentiation of high-grade glioma from primary central nervous system lymphoma: a systematic review and meta-analysis. PLoS One 2017;12:e0173430 doi:10.1371/journal.pone.0173430 pmid:28301491

   CrossRefPubMed
4. 4.↵
   2. Liang R,
   3. Li M,
   4. Wang X, et al

   . Role of rCBV values derived from dynamic susceptibility contrast-enhanced magnetic resonance imaging in differentiating CNS lymphoma from high grade glioma: a meta-analysis. Int J Clin Exp Med 2014;7:5573–77 pmid:25664074 pmid:25664074

   PubMed
5. 5.↵
   2. Kremer S,
   3. Grand S,
   4. Remy C, et al

   . Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol 2002;29:105–13 pmid:12297732

   PubMed
6. 6.↵
   2. Lu S,
   3. Gao Q,
   4. Yu J, et al

   . Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. Eur J Radiol 2016;85:1722–27 doi:10.1016/j.ejrad.2016.07.005 pmid:27666608

   CrossRefPubMed
7. 7.↵
   2. Kickingereder P,
   3. Sahm F,
   4. Wiestler B, et al

   . Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. AJNR Am J Neuroradiol 2014;35:1503–08 doi:10.3174/ajnr.A3915 pmid:24722313

   Abstract/FREE Full Text
8. 8.↵
   2. Koeller KK,
   3. Smirniotopoulos JG,
   4. Jones RV

   . Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 1997;17:1497–526 doi:10.1148/radiographics.17.6.9397461 pmid:9397461

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Zaharchuk G

   . Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. AJNR Am J Neuroradiol 2007;28:1850–58 doi:10.3174/ajnr.A0831 pmid:17998415

   Abstract/FREE Full Text
10. 10.↵
    2. Boxerman J,
    3. Schmainda K,
    4. Weisskoff R

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    Abstract/FREE Full Text
11. 11.↵
    2. Dandois V,
    3. De Coene B,
    4. Laloux P, et al

    . Increased relative cerebral blood volume (rCBV) in brain lymphoma. J Neuroradiol 2011;38:191–93 doi:10.1016/j.neurad.2010.06.004 pmid:20965569

    CrossRefPubMed
12. 12.↵
    2. Sugahara T,
    3. Korogi Y,
    4. Shigematsu Y, et al

    . Perfusion-sensitive MRI of cerebral lymphomas: a preliminary report. J Comput Assist Tomogr 1999;23:232–37 doi:10.1097/00004728-199903000-00011 pmid:10096330

    CrossRefPubMed
13. 13.↵
    2. Bjørnerud A,
    3. Sorensen AG,
    4. Mouridsen K, et al

    . T1- and T2*-dominant extravasation correction in DSC-MRI: part I, theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 2011;31:2041–53 doi:10.1038/jcbfm.2011.52 pmid:21505483

    CrossRefPubMed
14. 14.↵
    2. Bjørnerud A,
    3. Emblem K

    . Estimation of contrast agent extravasation from the tissue residue function: application to tumor perfusion imaging. In: Proceedings of the Scientific Meeting and Exhibition of the International Society of Magnetic Resonance in Medicine, Honolulu, Hawaii. April 18–24, 2009
15. 15.↵
    2. Emblem KE,
    3. Bjornerud A,
    4. Mouridsen K, et al

    . T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011;31:2054–64 doi:10.1038/jcbfm.2011.39 pmid:21505476

    CrossRefPubMed
16. 16.↵
    2. Weisskoff RM BJ,
    3. Sorensen AG,
    4. Kulke ST, et al

    . Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the Annual Meeting of the Society of Magnetic Resonance, San Francisco, California. August 6–12, 1994
17. 17.↵
    2. Sourbron S,
    3. Ingrisch M,
    4. Siefert A, et al

    . Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med 2009;62:205–17 doi:10.1002/mrm.22005 pmid:19449435

    CrossRefPubMed
18. 18.↵
    2. Park SH,
    3. Goo JM,
    4. Jo CH

    . Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 2004;5:11–18 doi:10.3348/kjr.2004.5.1.11 pmid:15064554

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Molnár PP,
    3. O'Neill BP,
    4. Scheithauer BW, et al

    . The blood-brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death. Neuro Oncol 1999;1:89–100 pmid:11550310

    CrossRefPubMed
20. 20.↵
    2. Jain R

    . Perfusion CT imaging of brain tumors: an overview. AJNR Am J Neuroradiol 2011;32:1570–77 doi:10.3174/ajnr.A2263 pmid:21051510

    Abstract/FREE Full Text
21. 21.↵
    2. Tofts PS,
    3. Brix G,
    4. Buckley DL, et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 doi:10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO%3B2-S pmid:10508281

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Boxerman JL,
    3. Paulson ES,
    4. Prah MA, et al

    . The effect of pulse sequence parameters and contrast agent dose on percentage signal recovery in DSC-MRI: implications for clinical applications. AJNR Am J Neuroradiol 2013;34:1364–69 doi:10.3174/ajnr.A3477 pmid:23413249

    Abstract/FREE Full Text
23. 23.↵
    2. Paulson ES,
    3. Schmainda KM

    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13 doi:10.1148/radiol.2492071659 pmid:18780827

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Levin JM,
    3. Kaufman MJ,
    4. Ross MH, et al

    . Sequential dynamic susceptibility contrast MR experiments in human brain: residual contrast agent effect, steady state, and hemodynamic perturbation. Magn Reson Med 1995;34:655–63 doi:10.1002/mrm.1910340503 pmid:8544685

    CrossRefPubMed
25. 25.↵
    2. Schramm P,
    3. Xyda A,
    4. Klotz E, et al

    . Dynamic CT perfusion imaging of intra-axial brain tumours: differentiation of high-grade gliomas from primary CNS lymphomas. Eur Radiol 2010;20:2482–90 doi:10.1007/s00330-010-1817-4 pmid:20495977

    CrossRefPubMed
26. 26.↵
    2. Onishi S,
    3. Kajiwara Y,
    4. Takayasu T, et al

    . NIMG-2: analysis of perfusion CT parameters for differentiating among glioblastoma, primary central nervous system lymphoma and brain metastasis. Neuro-Oncology 2017;19:vi146 doi:10.1093/neuonc/nox168.598

    CrossRef
27. 27.↵
    2. Ulmer S,
    3. Liess C,
    4. Otto N, et al

    . The mean transit time (MTT) reflects the amount of blood brain barrier breakdown due to microvascular proliferation in glioblastoma demonstrated by perfusion weighted imaging (PWI).
28. 28.↵
    2. Tietze A,
    3. Mouridsen K,
    4. Lassen-Ramshad Y, et al

    . Perfusion MRI derived indices of microvascular shunting and flow control correlate with tumor grade and outcome in patients with cerebral glioma. PLoS One 2015;10:e0123044 doi:10.1371/journal.pone.0123044 pmid:25875182

    CrossRefPubMed
29. 29.↵
    2. Mouridsen K,
    3. Hansen MB,
    4. Østergaard L, et al

    . Reliable estimation of capillary transit time distributions using DSC-MRI. J Cereb Blood Flow Metab 2014;34:1511–21 doi:10.1038/jcbfm.2014.111 pmid:24938401

    CrossRefPubMed
30. 30.↵
    2. Skinner JT,
    3. Moots PL,
    4. Ayers GD, et al

    . On the Use of DSC-MRI for measuring vascular permeability. AJNR Am J Neuroradiol 2016;37:80–87 doi:10.3174/ajnr.A4478 pmid:26427833

    Abstract/FREE Full Text
31. 31.↵
    2. Nguyen T,
    3. Cron G,
    4. Bezzina K, et al

    . Correlation of tumor immunohistochemistry with dynamic contrast-enhanced and DSC-MRI parameters in patients with gliomas. AJNR Am J Neuroradiol 2016;37:2217–23 doi:10.3174/ajnr.A4908 pmid:27585700

    Abstract/FREE Full Text